190 related articles for article (PubMed ID: 15018907)
1. Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence.
Jose B; Okamura S; Kato T; Nishino N; Sumida Y; Yoshida M
Bioorg Med Chem; 2004 Mar; 12(6):1351-6. PubMed ID: 15018907
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of a potent histone deacetylase inhibitor.
Liu T; Kapustin G; Etzkorn FA
J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
[TBL] [Abstract][Full Text] [Related]
4. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
[TBL] [Abstract][Full Text] [Related]
5. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
6. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
8. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
9. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
Wong JC; Hong R; Schreiber SL
J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
[TBL] [Abstract][Full Text] [Related]
10. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors that target tubulin.
Schemies J; Sippl W; Jung M
Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
[TBL] [Abstract][Full Text] [Related]
13. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
16. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Dallavalle S; Cincinelli R; Nannei R; Merlini L; Morini G; Penco S; Pisano C; Vesci L; Barbarino M; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2009 May; 44(5):1900-12. PubMed ID: 19084294
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
19. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
Jones P; Altamura S; De Francesco R; Gallinari P; Lahm A; Neddermann P; Rowley M; Serafini S; Steinkühler C
Bioorg Med Chem Lett; 2008 Mar; 18(6):1814-9. PubMed ID: 18308563
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222.
Rodriquez M; Terracciano S; Cini E; Settembrini G; Bruno I; Bifulco G; Taddei M; Gomez-Paloma L
Angew Chem Int Ed Engl; 2006 Jan; 45(3):423-7. PubMed ID: 16311994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
